PD09-05 PHASE 2/3 CLINICAL RESULTS OF IL-15RΑFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS) PATIENTS.

INTRODUCTION AND OBJECTIVE:Patients with NMIBC CIS unresponsive to BCG have limited treatment options. N-803 (Anktiva) is an mutant IL-15-based immunostimulatory fusion protein complex (IL-15RαFc) ...